Details of the Drug

General Information of Drug (ID: DMC3FOW)

Drug Name
Imsidolimab
Indication
Disease Entry ICD 11 Status REF
Generalized pustular psoriasis EA90.40 Phase 3 [1]
Drug Type
Monoclonal antibody
Cross-matching ID
TTD ID
DZ49IJ

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
IL-1 receptor-like 2 (IL1RL2) TTUS18T ILRL2_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT05366855) A Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Adult Subjects With Generalized Pustular Psoriasis. U.S.National Institutes of Health.
2 Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trial. Br J Dermatol. 2023 Jul 17;189(2):161-169.